At a glance
- FMT is well supported for recurrent C. difficile infection, where controlled trials show it prevents relapse far better than antibiotics alone.
- {“Two FDA-approved products now exist for that use”=>”one given rectally (Rebyota) and one as oral capsules (Vowst).”}
- For other conditions, including ulcerative colitis and irritable bowel syndrome, FMT is still experimental, and the American Gastroenterological Association advises against it outside clinical trials.
- Donor screening matters. Stool carries real infection risk, so do-it-yourself FMT is not equivalent to a screened, regulated product.
What it is
Fecal microbiota transplantation (FMT) moves processed stool from a screened, healthy donor into the digestive tract of a patient. The aim is to restore a healthier community of gut microbes where the patient’s own community has been disrupted.
Its best-known use is for Clostridioides difficile (C. difficile) infection. The antibiotics that treat this infection also disturb the normal gut community, and that disturbance is thought to leave room for C. difficile to return. In some people the infection comes back again and again. FMT is meant to break that cycle by re-establishing a more protective community.
How it is delivered
Donor material can be given in several ways: through a colonoscopy, as an enema, through a tube that passes through the nose into the small intestine, or as capsules.
Two standardized products are now FDA-approved for recurrent C. difficile infection. Rebyota (approved in 2022) is given rectally. Vowst (approved in 2023) is taken by mouth as capsules. [5]
Where the evidence is strongest
The clearest evidence is for recurrent C. difficile infection.
- In an early randomized trial, 81% of patients who received donor stool were cured after the first infusion, compared with 31% on standard vancomycin. The trial was small and was stopped after an interim analysis. [1]
- In ECOSPOR III, a placebo-controlled trial of 182 adults with repeated infections, 12% of those given the oral product (SER-109, now Vowst) had a recurrence within 8 weeks, compared with 40% on placebo. [2]
- The American Gastroenterological Association’s 2024 guideline suggests fecal microbiota–based therapy for adults with recurrent infection, selectively, after standard antibiotics. It also suggests conventional FMT for hospitalized adults with severe or fulminant infection that is not responding to antibiotics. [3][4]
Areas under investigation
Researchers are testing FMT in other conditions, especially inflammatory bowel disease.
A 2023 meta-analysis pooled 13 randomized trials of FMT in ulcerative colitis (580 patients). It found that clinical remission was more likely with FMT than with control treatment (risk ratio 1.73), with no significant difference in adverse events. The authors noted that reaching endoscopic remission and keeping people in remission over time remain difficult. [7]
Despite those signals, the AGA guideline recommends against conventional FMT for inflammatory bowel disease and irritable bowel syndrome outside clinical trials. [3][4] Interest in FMT for other conditions, including ones tied to the gut–brain connection, is mostly at an early stage. You can browse that work on Research.
Risks and safety considerations
FMT is a transfer of living organisms from another person, so screening is central to its safety.
- Infection from donor stool. In 2019 the FDA reported that two immunocompromised adults who received investigational FMT developed invasive infections with a drug-resistant E. coli, and one died. Both had received stool from the same donor, which had not been tested for that organism. The FDA called for donor questionnaires that address drug-resistant organism risk and for testing donor stool for these organisms. [6]
- Do-it-yourself FMT. Stool from an unscreened donor, such as a friend or family member, does not carry the protections that screened products do. The 2019 events show why screening matters.
- People with weakened immune systems. The AGA guideline suggests selective use of conventional FMT in mildly or moderately immunocompromised adults and advises against fecal microbiota–based therapy in severely immunocompromised adults. [3][4]
- The delivery method has its own risks. A colonoscopy, for example, carries the usual risks of the procedure and sedation. Short-term digestive symptoms after treatment are commonly reported.
Open questions
- Which donor features and which microbes are responsible for the benefit?
- What are the best route, dose, and number of treatments, and who should get them?
- How well do the benefits last, and what are the long-term safety effects?
- Can the results in recurrent C. difficile be repeated in other conditions, and in which patients?
- How will screening, regulation, and access evolve as more products reach the market?
Looking for the studies? Browse and filter them on Research.
References
- van Nood et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med, 2013 Early randomized trial of FMT against vancomycin.
- Feuerstadt et al. SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection (ECOSPOR III). N Engl J Med, 2022 Randomized, placebo-controlled trial of the oral product later approved as Vowst.
- AGA Clinical Practice Guideline on Fecal Microbiota–Based Therapies for Select Gastrointestinal Diseases (Peery et al., Gastroenterology, 2024) The guideline itself.
- CIDRAP. New guidelines recommend fecal microbiota transplant, related therapies for most patients with recurrent C diff News summary of the AGA guideline.
- Nixon Peabody. FDA approves microbiome-based therapies (Rebyota and Vowst) Overview of the two approvals.
- FDA. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms (2019)
- Efficacy and safety of fecal microbiota transplantation in the treatment of ulcerative colitis: a systematic review and meta-analysis (2023) Pooled 13 randomized trials.
- PubMed search — fecal microbiota transplantation To find newer studies.
- ClinicalTrials.gov search — fecal microbiota transplantation To find ongoing trials.